PaP Score — Palliative Prognostic Score
ورودیهای بالینی بیمار
حداقل ۵۰۰ — حداکثر ۱۰۰۰۰۰
حداقل ۰ — حداکثر ۱۰۰
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Group A0–5.5
- Group B5.5–11
- Group C11–17.5
The PaP Score — Palliative Prognostic Score calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include dyspnea. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
The PaP score estimates 30-day survival probability in advanced solid-tumor patients from 6 variables (dyspnea, anorexia, KPS, clinician prediction, WBC, lymphocyte %). Total 0-17.5.
Clinical Indication
The PaP Score — Palliative Prognostic Score is indicated for bedside clinical practice to support The PaP score estimates 30-day survival probability in advanced solid-tumor patients from 6 variables (dyspnea, anorexia, KPS, clinician prediction, WBC, lymphocyte %). Total 0-17.5.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival.
PaP = dyspnea (0/1.0) + anorexia (0/1.5) + KPS (>=50: 0; 30-40: 0; 10-20: 2.5) + clinician prediction of survival in weeks (>12: 0; 11-12: 2.0; 9-10: 2.5; 7-8: 2.5; 5-6: 4.5; 3-4: 6.0; 1-2: 8.5) + WBC (4800-8500: 0; 8501-11000: 0.5; >11000: 1.5) + lymphocytes % (20-40: 0; 12-19.9: 1.0; <12: 2.5). Range 0-17.5.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| dyspnea | boolean | Yes | Dyspnea present |
| anorexia | boolean | Yes | Anorexia present |
| kps | integer | Yes | Karnofsky performance status (%) |
| cps_weeks | integer | Yes | Clinician prediction of survival (weeks) |
| wbc | float | Yes | Total white blood count (cells/mm3) |
| lymphocyte_pct | float | Yes | Lymphocyte percentage (%) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–5.5 | Group A | Group A (0-5.5): >70% 30-day survival |
| 5.5–11 | Group B | Group B (5.6-11.0): 30-70% 30-day survival |
| 11–17.5 | Group C | Group C (11.1-17.5): <30% 30-day survival |
Evidence-Based References (EBM)
- Pirovano M, Maltoni M, Nanni O, et al. A new palliative prognostic score: a first step for the staging of terminally ill cancer patients. J Pain Symptom Manage. 1999;17(4):231-239.
- Maltoni M, Nanni O, Pirovano M, et al. Successful validation of the palliative prognostic score in terminally ill cancer patients. J Pain Symptom Manage. 1999;17(4):240-247.